{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:58:36Z","timestamp":1794675516034,"version":"4.9.1"},"publisher-location":"Cham","reference-count":46,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030637484","type":"print"},{"value":"9783030637491","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-63749-1_8","type":"book-chapter","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T03:03:02Z","timestamp":1621566182000},"page":"105-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer, the Media and Dealing with Knowledge"],"prefix":"10.1007","author":[{"given":"Florian","family":"Steger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Schochow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"8_CR1","volume-title":"Principles of biomedical ethics","author":"TL Beauchamp","year":"2013","unstructured":"Beauchamp TL, Childress JF (2013) Principles of biomedical ethics, 7th edn. Oxford University Press, New York","edition":"7"},{"key":"8_CR2","doi-asserted-by":"crossref","unstructured":"Beck K (2020) Kommunikationswissenschaft. 6th edn. UTB\u2013UVK, Stuttgart","DOI":"10.36198\/9783838553153"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","volume":"15","author":"R Chou","year":"2014","unstructured":"Chou R, Cruciani RA, Fiellin DA, Compton C, Farrar JT, Haigney MC, Inturrisi C, Knight JR, Otis-Green S, Marcus SM, Mehta D, Meyer MC, Portenoy R, Savage S, Strain E, Walsh S, Zeltzer L (2014) Methadone safety: a clinical practice guideline from the American pain society and college on problems of drug dependence, in collaboration with the heart rhythm society. J Pain 15:321\u2013337","journal-title":"J Pain"},{"key":"8_CR5","unstructured":"Cichy C (2017a) Plusminus. Methadon als Krebsmittel. Report, 12 Apr 2017. https:\/\/www.youtube.com\/watch?v=rcedV2gQ1V8. Accessed 25 Feb 2020"},{"key":"8_CR6","unstructured":"Cichy C (2017b) Plusminus. Methadon als Krebsmittel\u2014Die Reaktionen. Report, 18 Aug 2017. https:\/\/www.youtube.com\/watch?v=-7OeXoqdqDE. Accessed 25 Feb 2020"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s00481-017-0458-4","volume":"29","author":"B Dernbach","year":"2017","unstructured":"Dernbach B (2017) Medienethischer Kommentar zum Fall: \u201eMethadon zur Tumourtherapie\u201d. Ethik Med 29:330\u2013333","journal-title":"Ethik Med"},{"key":"8_CR9","first-page":"55","volume-title":"Goodman & Gilman\u2019s. The pharmacological basis of therapeutics","author":"MA Erickson","year":"2018","unstructured":"Erickson MA, Penning TM (2018) Drug Toxicity and Poisoning. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds) Goodman & Gilman\u2019s. The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 55\u201364"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1001\/jama.1992.03490170092032","volume":"268","author":"Evidence-Based Medicine Working Group","year":"1992","unstructured":"Evidence-Based Medicine Working Group (1992) Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 268:2420\u20132425","journal-title":"JAMA"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1399-6576.2008.01597.x","volume":"52","author":"OMS Fredheim","year":"2008","unstructured":"Fredheim OMS, Moksnes K, Borchgrevink PC, Kaasa S, Dale O (2008) Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 52:879\u2013889","journal-title":"Acta Anaesthesiol Scand"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1158\/0008-5472.CAN-08-1227","volume":"68","author":"C Friesen","year":"2008","unstructured":"Friesen C, Roscher M, Alt A, Miltner E (2008) Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, Kills Leukemia cells and overcomes chemoresistance. Can Res 68:6059\u20136064","journal-title":"Can Res"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.18632\/oncotarget.952","volume":"4","author":"C Friesen","year":"2013","unstructured":"Friesen C, Roscher M, Hormann I, Fichtner I, Alt A, Hilger RA, Debatin KM, Miltner E (2013) Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget 4:677\u2013690","journal-title":"Oncotarget"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.4161\/cc.28493","volume":"13","author":"C Friesen","year":"2014","unstructured":"Friesen C, Hormann I, Roscher M, Fichtner I, Alt A, Hilger R, Debatin KM, Miltner E (2014) Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle 13:1560\u20131570","journal-title":"Cell Cycle"},{"key":"8_CR3","unstructured":"German Federal Ministry of Education and Research (Bundesministerium f\u00fcr Bildung und Forschung, BMBF) (2019) Bekanntmachung: Richtlinie zur F\u00f6rderung klinischer Studienmit hoher Relevanz f\u00fcr die Patientenversorgung. Bundeszeiger vom 27 Feb 2018. https:\/\/www.bmbf.de\/foerderungen\/bekanntmachung-1609.html. Accessed 25 Feb 2020"},{"key":"8_CR15","unstructured":"German Rectors\u2019 Conference (Hochschulrektorenkonferenz, HRK) (1998) Empfehlung des 185. Plenums am 6. Juli 1998 in Bonn. Zum Umgang mit wissenschaftlichem Fehlverhalten in den Hochschulen. https:\/\/www.hrk.de\/uploads\/tx_szconvention\/Empfehlung_Zum_Umgang_mit_wissenschaftlichem_Fehlverhalten_in_den_Hochschulen_06071998.pdf. Accessed 25 Feb 2020"},{"key":"8_CR16","unstructured":"German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) (2013) Proposals for safeguarding good scientific practice. Recommendations of the commission on professional self-regulation in science. https:\/\/www.dfg.de\/download\/pdf\/dfg_im_profil\/reden_stellungnahmen\/download\/empfehlung_wiss_praxis_1310.pdf. Accessed 25 Feb 2020"},{"key":"8_CR17","unstructured":"German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) (2019) Code of conduct. Guidelines for safeguarding good research practice. https:\/\/www.dfg.de\/download\/pdf\/foerderung\/rechtliche_rahmenbedingungen\/gute_wissenschaftliche_praxis\/kodex_gwp_en.pdf. Accessed 25 Feb 2020"},{"key":"8_CR8","unstructured":"German Society for Palliative Medicine (Deutsche Gesellschaft f\u00fcr Palliativmedizin, DGP) (2017) Stellungnahme der Deutschen Gesellschaft f\u00fcr Palliativmedizin zum Einsatz von D,L-Methadon zur Tumortherapie. https:\/\/www.dgpalliativmedizin.de\/images\/20170705_DGP_Stellungnahme_Methadon.pdf. Accessed 25 Feb 2020"},{"key":"8_CR18","unstructured":"Gie\u00dfelmann K (2017a) Methadon in der Krebstherapie: Nicht ohne Absprache mit dem Onkologen. aerzteblatt.de. https:\/\/www.aerzteblatt.de\/treffer?mode=s&wo=49&s=methadon&typ=1&nid=77415. Accessed 25 Feb 2020"},{"key":"8_CR19","unstructured":"Gie\u00dfelmann K (2017b) Diskussion um potenzielle Anti-Tumour-Wirkung von Methadon. aertzteblatt.de. https:\/\/www.aerzteblatt.de\/nachrichten\/75734\/Diskussion-um-potenzielle-Anti-Tumour-Wirkung-von-Methadon. Accessed 25 Feb 2020"},{"key":"8_CR20","doi-asserted-by":"crossref","unstructured":"G\u00fcthle M, Friesen C, Hofheinz RD, Muche R, Ettrich TJ, Perkhofer L, Berger A, Seufferlein T (2015) Eine Phase I\/II-Studie zur Therapie mit D,L-Methadon in der Behandlung von Patienten mit histologisch gesicherten chemorefrakt\u00e4ren kolorektalen Karzinomen. Zeitschrift f\u00fcr Gastroenterologie 53:KG214","DOI":"10.1055\/s-0035-1559240"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, de Beer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Sch\u00fcnemann HJ (2011) GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394","journal-title":"J Clin Epidemiol"},{"key":"8_CR22","unstructured":"Hackenbroch V (2019) Das M\u00e4rchen vom Wundertest aus Heidelberg. Der Spiegel, 29 March 2019. https:\/\/www.spiegel.de\/wissenschaft\/brustkrebs-das-maerchen-vom-wundertest-aus-heidelberg-a-00000000-0002-0001-0000-000163155878. Accessed 25 Feb 2020"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/0895-4356(96)00019-4","volume":"49","author":"DC Hadorn","year":"1996","unstructured":"Hadorn DC, Baker D, Hodges JS, Hick N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749\u2013754","journal-title":"J Clin Epidemiol"},{"key":"8_CR24","unstructured":"Heinrich C (2015) Medizin-Innovation. Zur Krebsdiagnose reicht ein Blutstropfen. Der Spiegel,14 June 2015. https:\/\/www.spiegel.de\/gesundheit\/diagnose\/liquid-biopsy-den-krebs-durchs-blut-aufspueren-a-1036738.html. Accessed 25 Feb 2020"},{"key":"8_CR25","unstructured":"H\u00fcbner J, Hartmann M, Wedding U, Gie\u00dfler W, Schuler U, Hochhaus A (2017) Methadon in der Onkologie: \u201eStrohhalmfunktion\u201d ohne Evidenz. Deut \u00c4rzteblatt 114:A-1530\u2013A-1538"},{"key":"8_CR26","doi-asserted-by":"crossref","unstructured":"H\u00fctten F (2017) Methadon\u2014Wundermittel gegen Krebs? S\u00fcddeutsche Zeitung, 24 July 2017. https:\/\/www.sueddeutsche.de\/gesundheit\/medizin-methadon-wundermittel-gegen-krebs-1.3597694. Accessed 25 Feb 2020","DOI":"10.1007\/s15006-017-9142-3"},{"key":"8_CR27","first-page":"169","volume":"115","author":"A Jung","year":"2018","unstructured":"Jung A, Kirchner T (2018) Liquid biopsy in tumour genetic diagnosis. Deut \u00c4rzteblatt Int 115:169\u2013174","journal-title":"Deut \u00c4rzteblatt Int"},{"key":"8_CR28","unstructured":"Keller M (2018) \u00dcber Krebs und Hoffnung. Der Fall Methadon. Deutschlandfunk. https:\/\/www.deutschlandfunk.de\/ueber-krebs-und-hoffnung-der-fall-methadon.740.de.html?dram:article_id=414968. Accessed 25 Feb 2020"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp021113","volume":"1","author":"TR Kosten","year":"2002","unstructured":"Kosten TR, George TP (2002) The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 1:13\u201320","journal-title":"Sci Pract Perspect"},{"key":"8_CR31","unstructured":"Kotlorz T (2020) Erstmals klinische Studie zu Methadon in Krebstherapie. Pressemitteilung des Universit\u00e4tsklinikums Ulm. https:\/\/www.uniklinik-ulm.de\/aktuelles\/detailansicht\/news\/erstmals-klinische-studie-zu-methadon-in-krebstherapie.html?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=0b46497db07dfeca0181d278636d43ef. Accessed 25 Feb 2020"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.21873\/anticanres.13511","volume":"39","author":"V Landgraf","year":"2019","unstructured":"Landgraf V, Griessmann M, Roller J, Polednik C, Schmidt M (2019) DL-methadone as an enhancer of chemotherapeutic drugs in head and neck cancer cell lines. Anticancer Res 39:3633\u20133639","journal-title":"Anticancer Res"},{"issue":"Suppl 3","key":"8_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/neuonc\/noy139.264","volume":"20","author":"P Latzer","year":"2018","unstructured":"Latzer P, Kessler T, Sahm F, R\u00fcbmann P, Hielscher T, Platten M (2018) Methadone does not increase toxicity of temozolomide in glioblastoma cells. Neuro Oncol 20(Suppl 3):285","journal-title":"Neuro Oncol"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/TCRM.S40232","volume":"10","author":"C Lenk","year":"2014","unstructured":"Lenk C, Duttge G (2014) Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 10:537\u2013546","journal-title":"Ther Clin Risk Manag"},{"key":"8_CR35","unstructured":"Majorczyk S (2017) Methadon ist kein Wundermittel! Die Bild, 29 June 2017. https:\/\/www.bild.de\/ratgeber\/gesundheit\/methadon\/kommentar-methadon-in-der-krebstherapie-52381960.bild.html. Accessed 25 Feb 2020"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.300.15.1814","volume":"300","author":"VM Montori","year":"2008","unstructured":"Montori VM, Guyatt GH (2008) Progress in evidence-based medicine. JAMA 300:1814\u20131816","journal-title":"JAMA"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.21873\/anticanres.11438","volume":"37","author":"J Onken","year":"2017","unstructured":"Onken J, Friesen C, Vajkoczy P, Misch M (2017) Safety and tolerance of D,L-methadone in combination with chemotherapy in patients with glioma. Anticancer Res 37:1227\u20131235","journal-title":"Anticancer Res"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00280-019-03816-3","volume":"83","author":"H Oppermann","year":"2019","unstructured":"Oppermann H, Matusova M, Glasow A, Dietterle J, Baran-Schmidt R, Neumann K, Meixensberger J, Gaunitz F (2019) d, l-methadone does not improve radio- and chemotherapy in glioblastoma in vitro. Cancer Chemother Pharmacol 83:1017\u20131024","journal-title":"Cancer Chemother Pharmacol"},{"key":"8_CR39","unstructured":"Press Release (2019) Forscher des Universit\u00e4tsklinikums Heidelberg entwickeln ersten marktf\u00e4higen Bluttest f\u00fcr Brustkrebs. https:\/\/www.klinikum.uni-heidelberg.de\/newsroom\/forscher-des-universitatsklinikums-heidelberg-entwickeln-ersten-marktfahigen-bluttest-fur-brustkrebs\/. Accessed 25 Feb 2020"},{"key":"8_CR40","unstructured":"R\u00e9mi C, Bausewein C (2016) Zum Umgang mit Off-Label-Use in der Palliativmedizin. https:\/\/www.dgpalliativmedizin.de\/images\/161212_Offlabel_online.pdf. Accessed 25 Feb 2020"},{"key":"8_CR41","unstructured":"Schmude M (2017) Krebs-Diagnostik. Alternativ-Ansatz liquid biopsy. Deutschlandfunk, 15 Aug 2017. https:\/\/www.deutschlandfunk.de\/krebs-diagnostik-alternativ-ansatz-liquid-biopsy.676.de.html?dram:article_id=393537. Accessed 25 Feb 2020"},{"key":"8_CR42","first-page":"17","volume":"2","author":"U Schuler","year":"2017","unstructured":"Schuler U, W\u00f6rmann B, Arbeitskreis Palliativmedizin (2017) Methadon bei Krebspatienten: Zweifel an Wirksamkeit und Sicherheit. H\u00e4matologie und Onkologie. Mitglieder-Rundschreiben der DGHO 2:17\u201318","journal-title":"H\u00e4matologie Und Onkologie. Mitglieder-Rundschreiben Der DGHO"},{"key":"8_CR43","unstructured":"Schweitzer J, Kuhrt N (2017) Heroinersatz gegen Krebs. Die Zeit, 25 Sept 2017. https:\/\/www.zeit.de\/suche\/index?q=methadon+krebs. Accessed 25 Feb 2020"},{"key":"8_CR44","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00761-018-0445-5","volume":"24","author":"F Steger","year":"2018","unstructured":"Steger F, Gierschik P, Rubeis G (2018) Methadon gegen Krebs. Ethische Aspekte. Der Onkologe 24:915\u2013920","journal-title":"Ethische Aspekte. Der Onkologe"},{"key":"8_CR45","unstructured":"Stern TV (2017) Methadon gegen Krebs?\u2014Die ganze reportage. Broadcast 21 June 2017. https:\/\/www.youtube.com\/watch?v=Gc_9wdodz68. Accessed 25 Feb 2020"},{"key":"8_CR46","first-page":"1167","volume-title":"Goodman & Gilman\u2019s. The pharmacological basis of therapeutics","author":"A Wellstein","year":"2018","unstructured":"Wellstein A, Giaccone G, Atkins MB, Sausville EA (2018) Cytotoxic drugs. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds) Goodman & Gilman\u2019s. The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 1167\u20131201"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00481-017-0460-x","volume":"29","author":"E Winkler","year":"2017","unstructured":"Winkler E (2017) Methadon gegen Krebs\u2014auch eine Frage f\u00fcr die Ethik und Theorie der Medizin. Ethik Med 29:269\u2013272","journal-title":"Ethik Med"}],"container-title":["Recent Results in Cancer Research","Ethical Challenges in Cancer Diagnosis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-63749-1_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:43:01Z","timestamp":1672188181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-63749-1_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030637484","9783030637491"],"references-count":46,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-63749-1_8","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-030-63749-1","asserted-by":"object"}]},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"22 May 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}